StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report published on Friday. The firm issued a sell rating on the stock.
Advaxis Price Performance
Shares of ADXS stock opened at $2.86 on Friday. The company has a market cap of $5.19 million, a P/E ratio of -0.32 and a beta of 2.20. Advaxis has a twelve month low of $1.02 and a twelve month high of $44.80.
Get
Advaxis alerts:
Advaxis Company Profile
(Get Rating)
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
See Also
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report published on Friday. The firm issued a sell rating on the stock.
斯托克新闻网在周五发布的一份报告中对Advaxis(纳斯达克:ADXS-GET Rating)的股票进行了报道。该公司对该股发布了卖出评级。
Advaxis Price Performance
Shares of ADXS stock opened at $2.86 on Friday. The company has a market cap of $5.19 million, a P/E ratio of -0.32 and a beta of 2.20. Advaxis has a twelve month low of $1.02 and a twelve month high of $44.80.
上周五,ADXS股票开盘报2.86美元。该公司市值为519万美元,市盈率为-0.32,贝塔系数为2.20。Advaxis的12个月低点为1.02美元,12个月高位为44.80美元。
Get
Advaxis
alerts:
Advaxis Company Profile
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis,Inc.是一家临床阶段的生物技术公司,专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA,这是用于治疗转移性前列腺癌的第二阶段临床试验;ADXS-503,用于治疗非小细胞肺癌;以及ADXS-504,用于治疗前列腺癌。
See Also
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
- Upwork股价跌入便宜货领域
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。